Cargando…

Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis

Cerebral venous sinus thrombosis (CVST), accounting for less than 1% of stroke cases, is characterized by various causes, heterogeneous clinical presentation and different outcome. The plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms has been found to be associated with CVST. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogu, Anca Elena, Motoc, Andrei Gheorghe, Stroe, Alina Zorina, Docu Axelerad, Any, Docu Axelerad, Daniel, Petrica, Ligia, Jianu, Dragos Catalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146064/
https://www.ncbi.nlm.nih.gov/pubmed/33922851
http://dx.doi.org/10.3390/metabo11050266
_version_ 1783697313522253824
author Gogu, Anca Elena
Motoc, Andrei Gheorghe
Stroe, Alina Zorina
Docu Axelerad, Any
Docu Axelerad, Daniel
Petrica, Ligia
Jianu, Dragos Catalin
author_facet Gogu, Anca Elena
Motoc, Andrei Gheorghe
Stroe, Alina Zorina
Docu Axelerad, Any
Docu Axelerad, Daniel
Petrica, Ligia
Jianu, Dragos Catalin
author_sort Gogu, Anca Elena
collection PubMed
description Cerebral venous sinus thrombosis (CVST), accounting for less than 1% of stroke cases, is characterized by various causes, heterogeneous clinical presentation and different outcome. The plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms has been found to be associated with CVST. The aim of this retrospective study was to determine the potential association of PAI-1 675 4G/5G polymorphisms and homocysteine levels with cardiovascular risk factors in a group of young patients with CVST. Eighty patients with CVST and an equal number of age and sex matched controls were enrolled. The protocol included demographic and clinical baseline characteristics, neuroimagistic aspects, genetic testing (PAI-1 675 4G/5G polymorphisms), biochemical evaluation (homocysteine—tHcy, the lipid profile, blood glucose, glycohemoglobin—HbA1c, high-sensitive C-reactive protein—hsCRP) data, therapy and prognosis. The PAI-1 675 4G/5G gene polymorphisms were significantly correlated with increased homocysteine level (tHcy) (p < 0.05), higher total cholesterol (TC) (p < 0.05), low- density lipoprotein cholesterol (LDLc) (p = 0.05) and high- sensitive C- reactive protein (hsCRP) (p < 0.05) in patients with CVST when compared with controls. From the PAI-1 gene polymorphisms, the PAI-1 675 4G/5G genotype presented statistically significant values regarding the comparisons of the blood lipids values between the CVST group and control group. The homocysteine (tHcy) was increased in both groups, patients versus controls, in cases with the homozygous variant 4G/4G but the level was much higher in the group with CVST (50.56 µmol/L vs. 20.22 µmol/L; p = 0.03). The most common clinical presentation was headache (91.25%), followed by seizures (43.75%) and focal motor deficits (37.5%). The superior sagittal sinus (SSS) was the most commonly involved dural sinus (56.25%), followed by the lateral sinus (LS) (28.75%). Intima—media thickness (IMT) values were higher in the patients’ group with CVST (0.95 mm vs. 0.88 mm; p < 0.05). The fatal outcome occurred 2.5% of the time. PAI-1 675 4G/5G gene polymorphisms and higher homocysteine concentrations were found to be significantly associated with CVST in young patients.
format Online
Article
Text
id pubmed-8146064
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81460642021-05-26 Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis Gogu, Anca Elena Motoc, Andrei Gheorghe Stroe, Alina Zorina Docu Axelerad, Any Docu Axelerad, Daniel Petrica, Ligia Jianu, Dragos Catalin Metabolites Article Cerebral venous sinus thrombosis (CVST), accounting for less than 1% of stroke cases, is characterized by various causes, heterogeneous clinical presentation and different outcome. The plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms has been found to be associated with CVST. The aim of this retrospective study was to determine the potential association of PAI-1 675 4G/5G polymorphisms and homocysteine levels with cardiovascular risk factors in a group of young patients with CVST. Eighty patients with CVST and an equal number of age and sex matched controls were enrolled. The protocol included demographic and clinical baseline characteristics, neuroimagistic aspects, genetic testing (PAI-1 675 4G/5G polymorphisms), biochemical evaluation (homocysteine—tHcy, the lipid profile, blood glucose, glycohemoglobin—HbA1c, high-sensitive C-reactive protein—hsCRP) data, therapy and prognosis. The PAI-1 675 4G/5G gene polymorphisms were significantly correlated with increased homocysteine level (tHcy) (p < 0.05), higher total cholesterol (TC) (p < 0.05), low- density lipoprotein cholesterol (LDLc) (p = 0.05) and high- sensitive C- reactive protein (hsCRP) (p < 0.05) in patients with CVST when compared with controls. From the PAI-1 gene polymorphisms, the PAI-1 675 4G/5G genotype presented statistically significant values regarding the comparisons of the blood lipids values between the CVST group and control group. The homocysteine (tHcy) was increased in both groups, patients versus controls, in cases with the homozygous variant 4G/4G but the level was much higher in the group with CVST (50.56 µmol/L vs. 20.22 µmol/L; p = 0.03). The most common clinical presentation was headache (91.25%), followed by seizures (43.75%) and focal motor deficits (37.5%). The superior sagittal sinus (SSS) was the most commonly involved dural sinus (56.25%), followed by the lateral sinus (LS) (28.75%). Intima—media thickness (IMT) values were higher in the patients’ group with CVST (0.95 mm vs. 0.88 mm; p < 0.05). The fatal outcome occurred 2.5% of the time. PAI-1 675 4G/5G gene polymorphisms and higher homocysteine concentrations were found to be significantly associated with CVST in young patients. MDPI 2021-04-23 /pmc/articles/PMC8146064/ /pubmed/33922851 http://dx.doi.org/10.3390/metabo11050266 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gogu, Anca Elena
Motoc, Andrei Gheorghe
Stroe, Alina Zorina
Docu Axelerad, Any
Docu Axelerad, Daniel
Petrica, Ligia
Jianu, Dragos Catalin
Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title_full Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title_fullStr Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title_full_unstemmed Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title_short Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis
title_sort plasminogen activator inhibitor-1 (pai-1) gene polymorphisms associated with cardiovascular risk factors involved in cerebral venous sinus thrombosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146064/
https://www.ncbi.nlm.nih.gov/pubmed/33922851
http://dx.doi.org/10.3390/metabo11050266
work_keys_str_mv AT goguancaelena plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT motocandreigheorghe plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT stroealinazorina plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT docuaxeleradany plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT docuaxeleraddaniel plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT petricaligia plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis
AT jianudragoscatalin plasminogenactivatorinhibitor1pai1genepolymorphismsassociatedwithcardiovascularriskfactorsinvolvedincerebralvenoussinusthrombosis